NeuroKaire

Precision Medicine for Psychiatry and Neurology

Health Tech & Life Sciences
Active
Series A Tel Aviv-Yafo, Israel Founded 2018
Website ↗ LinkedIn
Last updated 2026-06-18
Total raised
$26.3M
Last: Grant 2026-05
Stage
Series A
Founded
2018
Headcount
46
HQ
Tel Aviv-Yafo, Israel
Sector
Health Tech & Life Sciences

About

NeuroKaire (formerly Genetika+) is developing a personalized medical testing tool to better treat depression by helping physicians find the best drug therapy for their patients. The NeuroKaire test predicts the best drug treatment for each patient, enabling faster treatment, fewer side effects, and lower dosing.

Funding history · 8 rounds · $26.3M total

2026-05
Grant $1.0M
BIRD Foundation
2024-06
A Round $10.0M
★ GreyBird VenturesJumpspeed VenturesMeron Capital
2022-09
Grant $2.5M
European Union’s EIC Fund
2021-09
A Round $10.0M
★ GreyBird VenturesMichael ZeisserHoward MorganMeron CapitalJumpspeed VenturesSapir Venture Partners
2020-07
Grant $1.0M
Israel Innovation Authority
2019-03
Grant $580K
Israel Innovation Authority
2018-11
Grant $40K
2018-10
Seed $1.1M
Jumpspeed VenturesSapir Venture PartnersHoward MorganMeron CapitalIsrael Innovation Authority

Q&A

What is NeuroKaire's primary focus?
NeuroKaire (formerly Genetika+) is developing a personalized medical testing tool to help physicians find the best drug therapy for patients with depression, aiming for faster treatment, fewer side effects, and lower dosing.
When was NeuroKaire founded?
NeuroKaire was founded in August 2018.
What is NeuroKaire's employee count?
NeuroKaire has 11-50 employees.
What was NeuroKaire's most recent funding round?
NeuroKaire secured a $1,000,000 grant in May 2026 from the BIRD Foundation.
Which investors participated in NeuroKaire's A Round in June 2024?
The A Round in June 2024 included GreyBird Ventures and Jumpspeed Ventures.
What was the amount raised in NeuroKaire's A Round in September 2021?
NeuroKaire raised $10,000,000 in an A Round in September 2021, led by GreyBird Ventures.
What is NeuroKaire's total funding raised to date?
NeuroKaire has raised a total of $26,270,000 USD.
Who are the co-founders of NeuroKaire?
The co-founders of NeuroKaire are Talia Cohen Solal (CEO) and Daphna Laifenfeld (CSO).

Team · 2

Talia Cohen Solal
Founder · Founder & CEO
LinkedIn ↗
Daphna Laifenfeld
Founder · CSO & Co-Founder,Member
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesDigital HealthcareDigital Medical DiagnosticsMedical Decision Support
Technologies
Artificial IntelligenceMachine Learning
Target customers
Healthcare & Life SciencesHealthcarePatientsProvidersLife SciencesPharmaceuticals
Business model
B2B2CB2B

Highlights

1 PatentsVerified

Tags

clinical-trialsneurologygenetic-engineeringpharma-companiesdeep-learningmental-healthmachine-learningdigital-healthcaremedicationdoctorspersonalizationtestingartificial-intelligenceclinicshealthcare-providerspatientsneurosciencehospitalspsychiatrydecision-support
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)